Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have advanced or metastatic non-small cell lung cancer that has not been previously treated with any chemotherapy.
Tumor/disease lesions that can be measured bidimensionally.
Must be able to carry-out work of light or sedentary nature (e.g. light house work, office work).
Adequate recovery from recent surgery or radiation therapy.
Must be at least 4 weeks from last major surgery or prior treatment with an investigational agent. At least 12 weeks from any radiation therapy to chest.
Accessible for treatment, follow-up and required visits at a participating center(s).
You may not be if
Prior chemotherapy or adjuvant chemotherapy for the treatment of lung cancer.
Prior treatment with cetuximab or other epidermal growth factor (EGFR)-targeted therapy.
Prior severe infusion reaction to antibody therapy.
Concurrent malignancy (previous malignancy without evidence of disease for 5 years will be allowed to enter trial).
Concurrent chemotherapy or therapy with another investigational agent not indicated in the protocol.
Serious uncontrolled medical disorders that would impair the ability to receive therapy.
History of myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure.
Sexually active and fertile individuals or partners of these individuals who are unwilling or unable to use an acceptable method of birth control for entire trial and up to 4 weeks after the study.
Women who are pregnant or breastfeeding.
Women with a positive pregnancy test on enrollment prior to study drug administration.
Altered mental status or psychiatric condition that prohibits understanding or rendering of consent.
Clareo Health | Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
